X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (169) 169
humans (166) 166
male (124) 124
female (119) 119
adult (116) 116
middle aged (100) 100
gastroenterology & hepatology (78) 78
aged (62) 62
antiviral agents - therapeutic use (58) 58
hepatitis c (50) 50
liver (46) 46
hepatitis (42) 42
hepatitis c, chronic - drug therapy (40) 40
drug therapy, combination (38) 38
interferon (38) 38
genotype (37) 37
young adult (37) 37
treatment outcome (36) 36
hepatitis c virus (34) 34
interferon-alpha - therapeutic use (34) 34
therapy (33) 33
antiviral agents - adverse effects (32) 32
ribavirin (31) 31
hepacivirus - genetics (30) 30
liver cirrhosis (30) 30
antiviral agents - administration & dosage (29) 29
viral load (29) 29
cirrhosis (28) 28
hepatitis b, chronic - drug therapy (28) 28
hcv (27) 27
fibrosis (25) 25
health aspects (25) 25
polyethylene glycols - therapeutic use (25) 25
adolescent (24) 24
genotypes (22) 22
ribavirin - therapeutic use (22) 22
patients (21) 21
prevalence (20) 20
virus-infection (20) 20
gastroenterology and hepatology (19) 19
hepatitis b (19) 19
interferon-alpha - adverse effects (19) 19
recombinant proteins (19) 19
risk factors (19) 19
analysis (18) 18
biomarkers - blood (18) 18
hepatitis c, chronic - virology (18) 18
infections (18) 18
infectious diseases (18) 18
interferon-alpha - administration & dosage (18) 18
antiviral agents (17) 17
care and treatment (17) 17
drug therapy (17) 17
hepacivirus - drug effects (17) 17
hepatology (17) 17
poland (17) 17
sustained virological response (17) 17
abridged index medicus (16) 16
infection (16) 16
lamivudine (16) 16
ribavirin - administration & dosage (16) 16
aged, 80 and over (15) 15
immunology (15) 15
poland - epidemiology (15) 15
rna, viral - blood (15) 15
safety (15) 15
virus diseases (15) 15
double-blind method (14) 14
hepatitis b virus - genetics (14) 14
hepatitis c - drug therapy (14) 14
hiv (14) 14
polyethylene glycols - adverse effects (14) 14
recombinant proteins - therapeutic use (14) 14
virology (14) 14
digestive system diseases (13) 13
epidemiology (13) 13
liver diseases (13) 13
medicine (13) 13
polyethylene glycols - administration & dosage (13) 13
treatment (13) 13
cd4 lymphocyte count (12) 12
disease (12) 12
gastroenterology (12) 12
genotype & phenotype (12) 12
hbv (12) 12
hcv infection (12) 12
hiv infections - drug therapy (12) 12
hiv infections - immunology (12) 12
liver - pathology (12) 12
pharmacology & pharmacy (12) 12
ribavirin - adverse effects (12) 12
viral hepatitis (12) 12
animals (11) 11
cytokines (11) 11
original (11) 11
recombinant proteins - administration & dosage (11) 11
alanine transaminase - blood (10) 10
biological response modifiers (10) 10
cell biology (10) 10
chronic infection (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1993 - 2001
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | EFFICACY | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HEPATITIS-C | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Maraviroc | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2008, Volume 359, Issue 23, pp. 2442 - 2455
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Hepatology, ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2018, Volume 23, Issue 2, pp. 149 - 156
Background: According to current recommendations diagnosis and management of HCV infection need detection and quantification of nucleic acids. In the era of... 
OMBITASVIR/PARITAPREVIR/RITONAVIR | INFECTIOUS DISEASES | EFFICACY | GENOTYPE | SAFETY | QUANTIFICATION | MONITOR | CHRONIC HEPATITIS-C | PREVALENCE | ACCURACY | VIROLOGY | DASABUVIR | PHARMACOLOGY & PHARMACY
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 5/2015, Volume 60, Issue 5, pp. 1457 - 1464
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 354 - 369